Spread the love

A study from the Department of Cancer Biology, Dana-Farber Cancer Institute;  Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA; and others shows that Cyclin D1–Cdk4 controls glucose metabolism independently of cell cycle progression.”

This study was published in the June 26, 2014 Nature [I.F >42] by Prof. Puigserver and others from the Department of Cancer Biology, Dana-Farber Cancer Institute;  Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMDreports here that: Molecular therapy for T2DM: MiRNA-603 promotes gluconeogenesis and hyperglycemia via up regulation of Cyclin D1. This study may suggest that MiRNA-603 by up regulating its target gene, it may inhibit  gluconeogenesis and hyperglycemia. Together, this study suggests that pharmacological formulations encompassing MiRNA-603 activators”  can be used in the treatment of NIDDM.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., MiRNA-based therapy for NIDDM: MiRNA-603 promotes gluconeogenesis and hyperglycemia via up regulation of Cyclin D1, 16/February/2014, 8.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love